MorphoSys (ETR:MOR) has been given a €64.00 ($76.19) price target by research analysts at HSBC in a research report issued to clients and investors on Friday. The firm presently has a “sell” rating on the stock. HSBC’s price target would indicate a potential downside of 22.80% from the company’s current price.
Several other research firms also recently weighed in on MOR. JPMorgan Chase & Co. reiterated a “buy” rating on shares of MorphoSys in a research note on Monday, January 15th. Goldman Sachs Group set a €72.00 ($85.71) target price on shares of MorphoSys and gave the stock a “neutral” rating in a research note on Wednesday, November 8th. Oddo Bhf set a €90.00 ($107.14) target price on shares of MorphoSys and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Deutsche Bank set a €90.00 ($107.14) target price on shares of MorphoSys and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Finally, Independent Research set a €93.00 ($110.71) target price on shares of MorphoSys and gave the stock a “buy” rating in a research note on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of €81.56 ($97.09).
MorphoSys (MOR) traded down €4.15 ($4.94) on Friday, hitting €82.90 ($98.69). 306,470 shares of the stock traded hands, compared to its average volume of 124,968. The stock has a market capitalization of $2,440.00 and a P/E ratio of -28.10. MorphoSys has a 52-week low of €47.10 ($56.07) and a 52-week high of €87.05 ($103.63).
COPYRIGHT VIOLATION WARNING: “HSBC Reiterates “€64.00” Price Target for MorphoSys (MOR)” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/21/hsbc-reiterates-64-00-price-target-for-morphosys-mor.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.